225 related articles for article (PubMed ID: 16082640)
1. Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy.
Davis JC; van der Heijde D; Dougados M; Woolley JM
Arthritis Rheum; 2005 Aug; 53(4):494-501. PubMed ID: 16082640
[TBL] [Abstract][Full Text] [Related]
2. Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept.
Boonen A; Patel V; Traina S; Chiou CF; Maetzel A; Tsuji W
J Rheumatol; 2008 Apr; 35(4):662-7. PubMed ID: 18278836
[TBL] [Abstract][Full Text] [Related]
3. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.
Heiberg MS; Nordvåg BY; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
Arthritis Rheum; 2005 Aug; 52(8):2506-12. PubMed ID: 16052584
[TBL] [Abstract][Full Text] [Related]
4. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
Braun J; McHugh N; Singh A; Wajdula JS; Sato R
Rheumatology (Oxford); 2007 Jun; 46(6):999-1004. PubMed ID: 17389658
[TBL] [Abstract][Full Text] [Related]
5. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
Brandt J; Khariouzov A; Listing J; Haibel H; Sörensen H; Grassnickel L; Rudwaleit M; Sieper J; Braun J
Arthritis Rheum; 2003 Jun; 48(6):1667-75. PubMed ID: 12794835
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study.
Davis JC; Revicki D; van der Heijde DM; Rentz AM; Wong RL; Kupper H; Luo MP
Arthritis Rheum; 2007 Aug; 57(6):1050-7. PubMed ID: 17665483
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
Krueger GG; Langley RG; Finlay AY; Griffiths CE; Woolley JM; Lalla D; Jahreis A
Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.
Brandt J; Listing J; Haibel H; Sörensen H; Schwebig A; Rudwaleit M; Sieper J; Braun J
Rheumatology (Oxford); 2005 Mar; 44(3):342-8. PubMed ID: 15561737
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response.
Kosinski M; Kujawski SC; Martin R; Wanke LA; Buatti MC; Ware JE; Perfetto EM
Am J Manag Care; 2002 Mar; 8(3):231-40. PubMed ID: 11915973
[TBL] [Abstract][Full Text] [Related]
10. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks.
Davis JC; van der Heijde DM; Braun J; Dougados M; Cush J; Clegg D; Inman RD; Kivitz A; Zhou L; Solinger A; Tsuji W
Ann Rheum Dis; 2005 Nov; 64(11):1557-62. PubMed ID: 15843448
[TBL] [Abstract][Full Text] [Related]
11. Responsiveness and discriminative capacity of the assessments in ankylosing spondylitis disease-controlling antirheumatic therapy core set and other outcome measures in a trial of etanercept in ankylosing spondylitis.
Wanders AJ; Gorman JD; Davis JC; Landewe RB; van der Heijde DM
Arthritis Rheum; 2004 Feb; 51(1):1-8. PubMed ID: 14872448
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis.
Mease PJ; Woolley JM; Singh A; Tsuji W; Dunn M; Chiou CF
J Rheumatol; 2010 Jun; 37(6):1221-7. PubMed ID: 20395648
[TBL] [Abstract][Full Text] [Related]
13. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
Gorman JD; Sack KE; Davis JC
N Engl J Med; 2002 May; 346(18):1349-56. PubMed ID: 11986408
[TBL] [Abstract][Full Text] [Related]
14. Etanercept in adult patients with early onset ankylosing spondylitis.
Inman RD; Clegg DO; Davis JC; Whitmore JB; Solinger A
J Rheumatol; 2006 Aug; 33(8):1634-6. PubMed ID: 16881118
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.
Calin A; Dijkmans BA; Emery P; Hakala M; Kalden J; Leirisalo-Repo M; Mola EM; Salvarani C; Sanmartí R; Sany J; Sibilia J; Sieper J; van der Linden S; Veys E; Appel AM; Fatenejad S
Ann Rheum Dis; 2004 Dec; 63(12):1594-600. PubMed ID: 15345498
[TBL] [Abstract][Full Text] [Related]
16. Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen.
Bennett RM; Schein J; Kosinski MR; Hewitt DJ; Jordan DM; Rosenthal NR
Arthritis Rheum; 2005 Aug; 53(4):519-27. PubMed ID: 16082646
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.
Davis JC; Van Der Heijde D; Braun J; Dougados M; Cush J; Clegg DO; Kivitz A; Fleischmann R; Inman R; Tsuji W;
Arthritis Rheum; 2003 Nov; 48(11):3230-6. PubMed ID: 14613288
[TBL] [Abstract][Full Text] [Related]
18. Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept.
Brandt J; Khariouzov A; Listing J; Haibel H; Sörensen H; Rudwaleit M; Sieper J; Braun J
J Rheumatol; 2004 Mar; 31(3):531-8. PubMed ID: 14994401
[TBL] [Abstract][Full Text] [Related]
19. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.
Baraliakos X; Brandt J; Listing J; Haibel H; Sörensen H; Rudwaleit M; Sieper J; Braun J
Arthritis Rheum; 2005 Dec; 53(6):856-63. PubMed ID: 16342093
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Ankylosing Spondylitis Quality of Life questionnaire: responsiveness of a new patient-reported outcome measure.
Packham JC; Jordan KP; Haywood KL; Garratt AM; Healey EL
Rheumatology (Oxford); 2012 Apr; 51(4):707-14. PubMed ID: 22179735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
